Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Saleh (Calgary, Canada), J. Fisher (Toronto, Canada), S. Provencher (Québec City, Canada), C. Ryerson (Vancouver, Canada), J. Weatherald (Calgary, Canada). Quality of online information on pulmonary arterial hypertension.. 1475

Member's Comments

No comment yet.

Related content which might interest you: An international survey of current pulmonary arterial hypertension (PAH) management Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 PROs: which instruments are available in pulmonary hypertension? Source: Virtual Congress 2020 – Pulmonary vascular diseases Year: 2020 Patient engagement and self-management in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 399-407 Year: 2016 Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension Source: Eur Respir J 2011; 38: 608-616 Year: 2011 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations Source: Eur Respir Rev, 28 (154) 190050; 10.1183/16000617.0050-2019 Year: 2019 Psychometric validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Correlations between clinical variables and quality of life in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan® Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Patient perspectives on exercise training in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017 Year: 2018 Risk assessment in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 390-398 Year: 2016 Idiopathic pulmonary arterial hypertension in the elderly: Data from the French registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Pulmonary arterial hypertension or left heart disease with pulmonary hypertension? Toward noninvasive clarity, but time for a new paradigm Source: Eur Respir J 2015; 46: 299-302 Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Current medical treatment of pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017